Evidence map›Paper›PMID 24166410›Full record

ArticleMolecular psychiatry2014

HPA axis genetic variation, cortisol and psychosis in major depression.

A F Schatzberg, J Keller, L Tennakoon, A Lembke, G Williams, F B Kraemer, J E Sarginson, L C Lazzeroni, G M Murphy

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Molecular psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. The HPA Axis as Target for Depression.Current neuropharmacology · 2024
    Article
  17. Article
  18. Review
  19. Targeting the Arginine Vasopressin VNeuropsychiatric disease and treatment · 2023
    Review
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

A F SchatzbergDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
J KellerDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
L TennakoonDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
A LembkeDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
G WilliamsDepartment of Medicine, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.
F B Kraemer1] Division of Endocrinology, Gerontology and Metabolism, VA Palo Alto Health Care System, Palo Alto, CA, USA [2] Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
J E SarginsonDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
L C LazzeroniDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
G M MurphyDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USBrigham and Women's Hospital · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4M
A BIOBEHAVIORAL RESEARCH TRAINING PROGRAMT32MH019938 · NIMH · STANFORD UNIVERSITY · PI Corey J Keller, RACHEL MANBER · 1994 to 2026
$9.4M
HPA AXIS/DOPAMINE INTERACTIONS IN PSYCHOTIC DEPRESSIONR01MH050604 · NIMH · STANFORD UNIVERSITY · PI SCHATZBERG, ALAN F. · 1994 to 2009
$5.2M
6/6 - The Genetics of Endophenotypes and SchizophreniaR01MH086135 · NIMH · STANFORD UNIVERSITY · PI LAZZERONI, LAURA C. · 2010 to 2013
$1.3M
LipolysisI01BX000398 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI KRAEMER, FREDRIC B. · 2009 to 2020
–
BLRD VA I01 BX000398NCATS NIH HHS UL1 TR001085NCRR NIH HHS UL1 RR025744NIMH NIH HHS MH19938NIMH NIH HHS MH50604NIMH NIH HHS R01 MH050604NIMH NIH HHS R01 MH086135NIMH NIH HHS T32 MH019938
6 · The paper itself

Abstract

Genetic variation underlying hypothalamic pituitary adrenal (HPA) axis overactivity in healthy controls (HCs) and patients with severe forms of major depression has not been well explored, but could explain risk for cortisol dysregulation. In total, 95 participants were studied: 40 patients with psychotic major depression (PMD); 26 patients with non-psychotic major depression (NPMD); and 29 HCs. Collection of genetic material was added one third of the way into a larger study on cortisol, cognition and psychosis in major depression. Subjects were assessed using the Brief Psychiatric Rating Scale, the Hamilton Depression Rating Scale and the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders. Blood was collected hourly for determination of cortisol from 1800 to 0900 h and for the assessment of alleles for six genes involved in HPA axis regulation. Two of the six genes contributed significantly to cortisol levels, psychosis measures or depression severity. After accounting for age, depression and psychosis, and medication status, only allelic variation for the glucocorticoid receptor (GR) gene accounted for a significant variance for mean cortisol levels from 1800 to 0100 h (r(2)=0.288) and from 0100 to 0900 h (r(2)=0.171). In addition, GR and corticotropin-releasing hormone receptor 1 (CRHR1) genotypes contributed significantly to psychosis measures and CRHR1 contributed significantly to depression severity rating.

Indexed as

AdultAffective Disorders, PsychoticCorticotropin-Releasing HormoneCRF Receptor, Type 1FemaleHumansHydrocortisoneHypothalamo-Hypophyseal SystemInterview, PsychologicalLinkage DisequilibriumMajor Depressive DisorderMalePituitary-Adrenal SystemPsychiatric Status Rating ScalesReceptors, Corticotropin-Releasing HormoneReceptors, GlucocorticoidCorticotropin-Releasing HormoneCRF Receptor, Type 1CRF receptor type 2HydrocortisoneNR3C1 protein, humanNR3C2 protein, humanReceptors, Corticotropin-Releasing HormoneReceptors, GlucocorticoidReceptors, MineralocorticoidTacrolimus Binding Protein 5Tacrolimus Binding Proteins

Identifiers

PMID24166410
PMCPMC4339288
OpenAlexW2031403268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.